These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19771540)

  • 41. Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes.
    Galbraith S; Marschner IC
    Stat Med; 2003 Jun; 22(11):1787-805. PubMed ID: 12754715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.
    Jennison C; Turnbull BW
    Biometrics; 1993 Sep; 49(3):741-52. PubMed ID: 8241370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stopping boundaries adjusted for sample size reestimation and negative stop.
    Shun Z
    J Biopharm Stat; 2002 Nov; 12(4):485-502. PubMed ID: 12477071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An algorithm for the design of group sequential triangular tests for single-arm clinical trials with a binary endpoint.
    McWilliams TP
    Stat Med; 2010 Nov; 29(27):2794-801. PubMed ID: 20860065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On the timing of a futility analysis in clinical trials.
    Pallay A
    J Biopharm Stat; 2000 Aug; 10(3):399-405. PubMed ID: 10959919
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Over-ruling a group sequential boundary--a stopping rule versus a guideline.
    Lan KK; Lachin JM; Bautista O
    Stat Med; 2003 Nov; 22(21):3347-55. PubMed ID: 14566919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of logrank tests and group sequential methods at fixed calendar times.
    DeMets DL; Gail MH
    Biometrics; 1985 Dec; 41(4):1039-44. PubMed ID: 4096915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Group sequential and adaptive designs: a novel, promising tool for nursing research.
    Baldi I; Gouchon SM; Di Giulio P; Buja A; Gregori D
    J Adv Nurs; 2011 Aug; 67(8):1824-33. PubMed ID: 21517937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Designs for efficient clinical trials.
    Simon R
    Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint.
    Hong S; Shi L
    Stat Med; 2012 Apr; 31(9):831-43. PubMed ID: 22302442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Computations for group sequential boundaries using the Lan-DeMets spending function method.
    Reboussin DM; DeMets DL; Kim KM; Lan KK
    Control Clin Trials; 2000 Jun; 21(3):190-207. PubMed ID: 10822118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials.
    Shimura M
    J Clin Pharm Ther; 2019 Apr; 44(2):243-248. PubMed ID: 30414384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interim analysis: the alpha spending function approach.
    DeMets DL; Lan KK
    Stat Med; 1994 Jul 15-30; 13(13-14):1341-52; discussion 1353-6. PubMed ID: 7973215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CP function: an alpha spending function based on conditional power.
    Jiang Z; Wang L; Li C; Xia J; Wang W
    Stat Med; 2014 Nov; 33(26):4501-14. PubMed ID: 25100033
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential methods and group sequential designs for comparative clinical trials.
    Sébille V; Bellissant E
    Fundam Clin Pharmacol; 2003 Oct; 17(5):505-16. PubMed ID: 14703713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An additive boundary for group sequential designs with connection to conditional error.
    Xi D; Gallo P
    Stat Med; 2019 Oct; 38(23):4656-4669. PubMed ID: 31338847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential methods based on the boundaries approach for the clinical comparison of survival times.
    Whitehead J
    Stat Med; 1994 Jul 15-30; 13(13-14):1357-68; discussion 1369-70. PubMed ID: 7973216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.